Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Phase 4 Unknown 480 enrolled Xiamen Innovax Biotech Co., Ltd Zhejiang Provincial Center for Disease Control and Prevention · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with recombinant human papillomavirus bivalent (Types 16,18) vaccine (Escherichia coli) and Hepatitis E vaccine (Escherichia coli)

Timeline

Start: 2021-10-25
Primary completion: 2022-11-30
Completion: 2023-06-10

Publications

Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cecolin	Vaccine	—	—
Subject	Hecolin®	Vaccine	—	—

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Summary

Timeline

Publications

Drugs

Indications